Innate Pharma (IPHA) Invested Capital (2017 - 2025)

Innate Pharma has reported Invested Capital for 9 years, with the latest figure at $1.0 million in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital fell 97.63% year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (down 97.63% YoY), and the FY2025 full-year result was $1.0 million, down 97.63% from the prior year.
• Invested Capital for Q4 2025 stood at $1.0 million, down from $15.9 million in the prior quarter.
• The five-year high for Invested Capital was $173.5 million in Q4 2021, with the low at $1.0 million in Q4 2025.
• Historically, Invested Capital has averaged $86.0 million across 5 years, with a median of $83.6 million in 2022.
• Annual changes were most pronounced in 2021 — Invested Capital tumbled 99.92% — and 2023, when it advanced 0.42%.
• Innate Pharma's Invested Capital stood at $173.5 million in 2021, then sank by 43.32% to $98.4 million in 2022, then grew by 0.42% to $98.8 million in 2023, then tumbled by 56.91% to $42.6 million in 2024, then plunged by 97.63% to $1.0 million in 2025.
• The last three Invested Capital figures came in at $1.0 million (Q4 2025), $15.9 million (Q2 2025), and $42.6 million (Q4 2024), per Business Quant data.